Suppr超能文献

靶向破坏 idol 基因可改变固醇和肝 X 受体激动剂对低密度脂蛋白受体的细胞调控。

Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.

机构信息

Howard Hughes Medical Institute, UCLA School of Medicine, Box 951662, Los Angeles, CA 90095-1662, USA.

出版信息

Mol Cell Biol. 2011 May;31(9):1885-93. doi: 10.1128/MCB.01469-10. Epub 2011 Feb 22.

Abstract

Previously, we identified the E3 ubiquitin ligase Idol (inducible degrader of the low-density lipoprotein [LDL] receptor [LDLR]) as a posttranscriptional regulator of the LDLR pathway. Idol stimulates LDLR degradation through ubiquitination of its C-terminal domain, thereby limiting cholesterol uptake. Here we report the generation and characterization of mouse embryonic stem cells homozygous for a null mutation in the Idol gene. Cells lacking Idol exhibit markedly elevated levels of the LDLR protein and increased rates of LDL uptake. Furthermore, despite an intact sterol responsive element-binding protein (SREBP) pathway, Idol-null cells exhibit an altered response to multiple regulators of sterol metabolism, including serum, oxysterols, and synthetic liver X receptor (LXR) agonists. The ability of oxysterols and lipoprotein-containing serum to suppress LDLR protein levels is reduced, and the time course of suppression is delayed, in cells lacking Idol. LXR ligands have no effect on LDLR levels in Idol-null cells, indicating that Idol is required for LXR-dependent inhibition of the LDLR pathway. In line with these results, the half-life of the LDLR protein is prolonged in the absence of Idol. Finally, the ability of statins and PCSK9 to alter LDLR levels is independent of, and additive with, the LXR-Idol pathway. These results demonstrate that the LXR-Idol pathway is an important contributor to feedback inhibition of the LDLR by sterols and a biological determinant of cellular LDL uptake.

摘要

先前,我们发现 E3 泛素连接酶 Idol(低密度脂蛋白受体[LDLR]的可诱导降解物)是 LDLR 途径的转录后调节剂。Idol 通过其 C 端结构域的泛素化刺激 LDLR 降解,从而限制胆固醇摄取。在这里,我们报告了 LDLR 基因缺失突变的小鼠胚胎干细胞的产生和特征。缺乏 Idol 的细胞表现出 LDLR 蛋白水平显著升高和 LDL 摄取率增加。此外,尽管固醇反应元件结合蛋白(SREBP)途径完整,但 Idol 缺失细胞对固醇代谢的多种调节剂(包括血清、氧化固醇和合成肝 X 受体[LXR]激动剂)的反应发生改变。缺乏 Idol 的细胞中,氧化固醇和含脂蛋白的血清降低 LDLR 蛋白水平的能力降低,抑制的时间过程延迟。LXR 配体对 Idol 缺失细胞中的 LDLR 水平没有影响,表明 Idol 是 LXR 依赖性 LDLR 途径抑制所必需的。与这些结果一致,在缺乏 Idol 的情况下,LDLR 蛋白的半衰期延长。最后,他汀类药物和 PCSK9 改变 LDLR 水平的能力与 LXR-Idol 途径无关,并且是 LDL 摄取的细胞的生物学决定因素。这些结果表明,LXR-Idol 途径是固醇对 LDLR 反馈抑制的重要贡献者,也是细胞 LDL 摄取的生物学决定因素。

相似文献

4
Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2541-6. doi: 10.1161/ATVBAHA.112.250571. Epub 2012 Aug 30.
5
The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.
J Biol Chem. 2010 Jun 25;285(26):19720-6. doi: 10.1074/jbc.M110.123729. Epub 2010 Apr 28.
6
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
Science. 2009 Jul 3;325(5936):100-4. doi: 10.1126/science.1168974. Epub 2009 Jun 11.

引用本文的文献

2
Engineering lentivirus envelope VSV-G for liver targeted delivery of IDOL-shRNA to ameliorate hypercholesterolemia and atherosclerosis.
Mol Ther Nucleic Acids. 2024 Jan 11;35(1):102115. doi: 10.1016/j.omtn.2024.102115. eCollection 2024 Mar 12.
3
25-Hydroxycholesterol in health and diseases.
J Lipid Res. 2024 Jan;65(1):100486. doi: 10.1016/j.jlr.2023.100486. Epub 2023 Dec 16.
4
Liver X Receptor-Inducible Host E3 Ligase IDOL Targets a Human Cytomegalovirus Reactivation Determinant.
J Virol. 2023 Jul 27;97(7):e0075823. doi: 10.1128/jvi.00758-23. Epub 2023 Jun 20.
5
Mechanism of the Regulation of Plasma Cholesterol Levels by PI(4,5)P.
Adv Exp Med Biol. 2023;1422:89-119. doi: 10.1007/978-3-031-21547-6_3.
6
Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases.
Front Med (Lausanne). 2023 Feb 2;10:1102469. doi: 10.3389/fmed.2023.1102469. eCollection 2023.
7
Pathways and Mechanisms of Cellular Cholesterol Efflux-Insight From Imaging.
Front Cell Dev Biol. 2022 Mar 1;10:834408. doi: 10.3389/fcell.2022.834408. eCollection 2022.
10
LDL Receptor Pathway Regulation by miR-224 and miR-520d.
Front Cardiovasc Med. 2020 May 22;7:81. doi: 10.3389/fcvm.2020.00081. eCollection 2020.

本文引用的文献

1
The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.
J Biol Chem. 2010 Jun 25;285(26):19720-6. doi: 10.1074/jbc.M110.123729. Epub 2010 Apr 28.
3
LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
Science. 2009 Jul 3;325(5936):100-4. doi: 10.1126/science.1168974. Epub 2009 Jun 11.
4
Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels.
Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9546-7. doi: 10.1073/pnas.0904560106. Epub 2009 Jun 8.
5
Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.
J Biol Chem. 2009 Apr 17;284(16):10561-70. doi: 10.1074/jbc.M808802200. Epub 2009 Feb 17.
6
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Biochem Biophys Res Commun. 2008 Oct 10;375(1):69-73. doi: 10.1016/j.bbrc.2008.07.106. Epub 2008 Jul 31.
7
Investigations on the evolutionary conservation of PCSK9 reveal a functionally important protrusion.
FEBS J. 2008 Aug;275(16):4121-33. doi: 10.1111/j.1742-4658.2008.06553.x. Epub 2008 Jul 9.
8
The effect of T0901317 on ATP-binding cassette transporter A1 and Niemann-Pick type C1 in apoE-/- mice.
J Cardiovasc Pharmacol. 2008 May;51(5):467-75. doi: 10.1097/FJC.0b013e31816a5be3.
9
Plasma PCSK9 preferentially reduces liver LDL receptors in mice.
J Lipid Res. 2008 Jun;49(6):1303-11. doi: 10.1194/jlr.M800027-JLR200. Epub 2008 Mar 19.
10
PCSK9: an enigmatic protease.
Biochim Biophys Acta. 2008 Apr;1781(4):184-91. doi: 10.1016/j.bbalip.2008.01.003. Epub 2008 Feb 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验